ERECTILE DYSFUNCTION MARKET SIZE IS EXPECTED TO CROSS USD 4.7 BILLION BY 2026

Erectile Dysfunction Market Size, Share, Trends Analysis Report by Products (Drugs and Devices); Drugs (ROA – Oral Drugs, Topical Formulation, Penile Injections & Suppositories and Distribution - Hospital Pharmacies, Offline Retail Pharmacies, and Online Channels); Devices (Penile Implants, Vacuum Therapy Devices, Shockwave Therapy, and Others); and Geography (North America, Europe, APAC, Latin America, and the Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

345 Pages

icon-table

110 Tables

icon-chart

151 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

46 Companies

icon-market

5 Market Segment

Erectile Dysfunction Market Report Scope

Report Attribute Details
MARKET SIZE (REVENUE) 4.7 BILLION (2026)
Base Year 2020
Forecast Year 2021–2026
Market Segments Products (Drugs and Devices); Drugs (ROA – Oral Drugs, Topical Formulation, Penile Injections & Suppositories and Distribution - Hospital Pharmacies, Offline Retail Pharmacies, and Online Channels); Devices (Penile Implants, Vacuum Therapy Devices, Shockwave Therapy, and Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, Saudi Arabia, UAE, and South Africa

INDUSTRY INSIGHTS

The global erectile dysfunction market size will be valued at USD 4.7 billion by 2026. The APAC region is projected to grow at the highest CAGR during 2021–2026 due to the increase in the aging population and high incidence of diabetes, hypertension, and cardiovascular diseases. The global erectile dysfunction market is expected to observe a negative growth during the forecast period because of the decline in revenue from the ED therapeutics segment. The presence of several generic companies and the patent expiry of blockbuster ED drugs, including Viagra, Cialis, and Levitra, are expected to hamper ED drugs' growth. However, the overall market is expected to benefit from the steady growth observed in ED devices. The non-invasive nature and no adverse effects profile of shock wave therapy are the primary factors influencing the ED device market's growth. The increasing focus of vendors in manufacturing new innovative technologies such as vibrators and magnetic therapy for the management of ED is further boosting the ED devices market. The introduction of magnetic therapy for the treatment of ED is likely to drive the demand for ED devices. However, the outbreak of the COVID-19 pandemic and hospitals' unavailability for penile implantations hindered the ED devices market in 2020. Nevertheless, a high incidence of the disease followed by the wide availability of generic medications and advanced technological advances in ED devices are likely to boost the market during the forecast period.

SNIPPETS

  • The ED devices segment is expected to grow at the highest CAGR during the forecast period because of the increase in the adoption of penile implants, vacuum constriction devices, and shock wave therapies.
  • Retail pharmacies are projected to touch revenue figures of over $1.7 billion by 2026 due to the increased accessibility and penetration of these stores.
  • North America is likely to reach a $1.5 billion revenue by 2026, owing to the high prevalence of erectile dysfunction in the US population.
  • The APAC region is projected to grow at the highest CAGR during 2020–2026 due to the increase in the aging population and high incidence of diabetes, hypertension, and cardiovascular diseases.

GLOBAL ERECTILE DYSFUNCTION MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Product
  • Drugs
  • Devices
  • Distribution
  • Geography

INSIGHTS BY PRODUCTS

Erectile Dysfunction (ED) drugs occupy the major share of the ED drugs market due to physicians' high recommendations and high efficiency. The advent of topical formulations and innovations in minimal invasive penile suppositories is likely to boost the market during the forecast period. Oral drugs consist of PDE-5 inhibitors, which are considered as the first-line treatment option by physicians for the treatment of ED. However, the oral drug sub-segment is experiencing a negative CAGR due to the loss of patent protection. 

ED devices are anticipated to grow at a CAGR of over 3% during the forecast period. The growth can be attributed to increased innovations in ED devices. Penile implants constitute the majority of share in the ED devices segment. Furthermore, the non-invasive nature and no adverse effects profile of shock wave therapy is a primary factor driving the ED devices market. The increasing focus of vendors in manufacturing new innovative technologies such as vibrators and magnetic therapy for the management of ED also influences the growth. The Introduction of magnetic therapy for treating the disease is also likely to boost the device market in the future. However, the COVID-19 outbreak and hospitals' unavailability for penile implantations or surgeries hampered growth in 2020.

INSIGHTS BY DRUGS

Oral drugs are found to be more effective and safe drugs and are considered first-line therapy in the treatment of ED. Hence, these drugs account for over 94% share of the market. Innovations in oral PDE-5 inhibitors include novel oral transmucosal drug delivery through oral dispersive tablets, or oral dispersible film is expected to boost market growth during the forecast period. The high prevalence of vascular and chronic diseases such as diabetes, hypertension, psychological disorders, etc., is likely to influence segment growth. 

An increase in the failure rates of oral medications for ED, which are as high as 60% in some patient populations, and increasing efficacy of injectable medication are important factors driving patients to opt for penile injections. Intracavernosal injections are considered as an alternative for oral PDE-5 inhibitors due to increasing effectiveness and sufficient erection. Penile injections are preferable for patients that are contraindicated for oral PDE-5 inhibitors or intolerable to oral medications, reliable rigidity, and rapid onset of erection. However, complications with penile injections such as priapism, failures to respond to intracavernosal or intraurethral injections, and increased efficacy of oral medications limit the growth of penile injections.

INSIGHTS BY DEVICES

Based on device type, penile implants dominate the device market, accounting for over 49% shares, followed by VCD (vacuum constriction devices) and shockwave therapy. Penile implantations are recommended when the patient fails to respond via oral PDE-5 inhibitors or penile injections. Although penile implantations are considered the last option by physicians, their demand increases due to the high efficacy of up to 90% satisfactory erection among patients. However, malfunctioning, erosions, infections, lack of medical expertise about implantation, and the high cost of implants are expected to hamper the growth of penile implantations.

Vacuum constriction devices (VCD) accounted for over 39% of the global erectile dysfunction devices market in 2020. These devices are experiencing growth owing to their non-invasive nature and high patient satisfaction. Over 90% of the patient population experienced successful erectile function with VCD, thereby boosting the market growth. North America dominates ED devices' usage due to the high accessibility to healthcare infrastructure, high prevalence of ED disorder, and increasing chronic health disorders. Furthermore, APAC is also observed to have increased growth due to an increase in disease awareness.

INSIGHTS BY DISTRIBUTION

Retail pharmacies account for the largest share of the global ED drugs market. Retail pharmacies are considered major centers to procure medicines. Easy access to medicines and the availability of generic ED drugs via retail pharmacies increase the market share of retail pharmacies. Hospital pharmacies constituted over 33% shares in the market. The growing awareness of erectile dysfunction and other sex-related disorders has highly increased the revenue of hospitals. Developed countries are the major contributors to hospital pharmacies as patients prefer prescribed medication for ED. However, hospital pharmacies experienced negative growth in 2020 due to the outbreak of the COVID-19 pandemic.

Online portals play a major role in delivering erectile dysfunction drugs. Ease access to medications and decreased social stigma regarding sexual dysfunctions are major factors leading to segment growth. The accessibility of online portals by pharmaceutical companies such as Pfizer, Cipla providing ED medication through CiplaMed and Viagra website increases patient treatment preference. Online portals experienced higher growth in 2020 than retail pharmacies and hospital pharmacies due to the COVID-19 pandemic, which increased the online purchase of medicines.

INSIGHTS BY GEOGRAPHY

The increasing focus on strategic agreements and collaborations is driving the North American ED market. The region accounted for shares of around 37% of the total erectile dysfunction market share. Factors contributing to the growth include better access to erectile dysfunction prescription and generic drugs, reimbursement coverage for surgeries in ED, better healthcare infrastructure, increase in R&D innovations, high demand for ED drugs are likely to drive the market. The US is a major contributor to the North America region, accounting for over 90% of the market share. Approximately 18 million men are affected by erectile dysfunction in the US. With the increase in chronic diseases, the incidence of ED is growing. Over 50% and 51.3% of people with cardiovascular diseases and diabetes, respectively, are likely to experience erectile dysfunction. 

INSIGHTS BY VENDORS

The global ED drugs market is observed to be oligopoly in nature, wherein only a few sellers occupy the dominant market share. Pfizer, Eli Lilly and Company, Bayer, Teva Pharmaceuticals, Viatris, Dong-A-Socio Holdings, and Vivus are the key players offering oral ED drugs. Although the blockbuster oral drugs of ED lost their patent protection, the drug market is expected to witness sustainable growth due to the high availability of generic versions. Branded drugs offered by global players are introduced as generic drugs for treating ED. The competitiveness among vendors is significantly high because of the accessibility to a wide range of low-cost generic drugs and OTC topical drug formulations for treating ED. Companies whose patents expired are expected to face strong competition from vendors offering generic drugs, topical creams, and non-invasive options.

The global erectile dysfunction market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Segmentation by Products

  • Drugs
  • Devices

By Drugs

  • Route of Administration
    • Oral Drugs
    • Topical Formulation
    • Penile Injections & Suppositories
  • Distribution
    • Hospital Pharmacies
    • Offline Retail Pharmacies
    • Online Channels

By Devices

  • Penile Implants
  • Vacuum Therapy Devices
  • Shockwave Therapy
  • Others

By Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa

Frequently Asked Questions

What is the market size of the erectile dysfunction market during the period 2021-2026?

The global erectile dysfunction market is expected to reach revenue of over USD 4.7 billion by 2026.

Which new ED devices are introduced for the treatment of erectile dysfunction?

Low-intensity shock wave extracorporeal therapies, tissue engineering, gene therapies, nanotechnology, stem cell therapies, and endovascular technology are some of the latest devices introduced in the market.

What are the threats faced by the existing key players in the ED industry?

Patent expiries are the major threat faced by the existing key players.

Which distribution channels is expected to contribute highest revenue to the erectile dysfunction treatment market?

Retail pharmacies are expected to account for the highest revenue during the forecast period.

Which region to account for the highest incremental revenue during the forecast period?

The APAC region is expected to contribute the highest incremental revenue during the forecast period.

Download Free Sample

The global erectile dysfunction is expected to cross USD 4.7 billion by 2026.

The following factors are likely to contribute to the growth of the erectile dysfunction market during the forecast period:

  • Introduction of New ED Treatment Devices
  • Increase in Strategic Agreements & Collaborations
  • Advances in ED Drug Formulations
  • Increase in Incidence of ED and Other Chronic Diseases

Base Year:                  2020

Forecast Year:           2021–2026

The study considers the present scenario of the erectile dysfunction market and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Prominent Vendors

  • Eli Lilly and Company
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • VIVUS
  • Pfizer
  • Bayer
  • Boston Scientific
  • Coloplast
  • Teva Pharmaceuticals
  • Viatris
  • Dong-A Socio Holdings

Other Prominent Vendors

  • Aurobindo Pharma
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Dr. Reddy’s Laboratories
  • Cristalia
  • Metuchen Pharmaceuticals
  • Menarini Group
  • SK Chemicals
  • Seelos Therapeutics
  • GlaxoSmithKline
  • Sanofi
  • Lupin
  • Cipla
  • Sandoz
  • Endo International
  • Ferring Pharmaceuticals
  • ADVANZ PHARMA
  • Alembic Pharmaceuticals
  • Guangzhou Pharmaceutical Holdings
  • iX Biopharma
  • Dornier MedTech
  • Zephyr Surgical Implants
  • Augusta Medical Systems
  • Launch Medical
  • Bonro Medical
  • Owen Mumford
  • Direx Group
  • Zimmer Medizin Systeme
  • MTS Medical UG
  • Medispec
  • Inceler Medical
  • NOVAmedtek
  • WIKKON
  • Top Quality Group
  • Promedon
  • Timm Medical Technologies
  • Global Life Technologies
  • Urology Health Store
  • Hims

Products

  • Drugs
  • Devices

Drugs

  • Route of Administration
    • Oral Drugs
    • Topical Formulation
    • Penile Injections & Suppositories
  • Distribution
    • Hospital Pharmacies
    • Offline Retail Pharmacies
    • Online Channels

Devices

  • Penile Implants
  • Vacuum Therapy Devices
  • Shockwave Therapy
  • Others

Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusion

4.2 Base Year

4.3 Scope of The Study

4.4 Market Segments

4.4.1 Market Segmentation by Product

4.4.2 ED Drugs Market Segmentation by ROA

4.4.3 ED Drugs Market Segmentation by Distribution

4.4.4 ED Devices Market Segmentation by Product

4.4.5 Market Segmentation by Geography

5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 Market at a Glance

7 Introduction

7.1 Overview

7.1.1 Signs & Symptoms Of ED

7.1.2 Classification of ED

7.1.3 Etiology of ED

7.1.4 Epidemiology

7.1.5 Diagnosis & Treatment of ED

7.1.6 ED Treatment

8 Pipeline Landscape

8.1 Overview

8.2 Key Investigational Drugs/Devices

8.3 Terminated/Withdrawn Drug/Device Candidates

8.4 Key Product Profiles

8.4.1 MED3000

8.4.2 YM178

8.4.3 SST-6006

9 Marketed Product Landscape

9.1 Overview

9.2 Comparision of ED Pharmaceuticals

9.2.1 Comparison of Pharmacological Drugs For ED

9.2.2 Comparison of ED Devices

10 Market Opportunities & Trends

10.1 Emergence Of Innovative Ed Treatment Technologies

10.2 Increasing Strategic Agreements & Collaborations

10.3 Increase In E-Commerce Delivery Of ED Drugs & Devices

10.4 Advancements In ED Drug Formulations

11 Market Growth Enablers

11.1 Increasing Incidence Of Erectile Dysfunction And Other Chronic Diseases

11.2 Advancements In Erectile Dysfunction Treatment Devices

11.3 Topical Formulation As A New Treatment For Impotence

12 Market Restraints

12.1 Low Patient Compliance Toward ED Treatment

12.2 Key Patent Expiries & Availability Of Low-Cost Generics

12.3 Complications Associated With Erectile Drugs & Devices

12.4 Availability Of Alternative Treatments For ED

12.5 Threat From Counterfeit Drugs In Treating Erectile Dysfunction

13 Market Landscape

13.1 Market Overview

13.2 Market Size & Forecast

13.3 Five Forces Analysis

13.3.1 Threat of New Entrants

13.3.2 Bargaining Power of Suppliers

13.3.3 Bargaining Power of Buyers

13.3.4 Threat of Substitutes

13.3.5 Competitive Rivalry

14 Product

14.1 Market Snapshot & Growth Engine

14.2 Market Overview

15 Drugs

15.1 Market Overview

15.1.1 COVID-19 Impact on Erectile Dysfunction Drugs Market

15.2 Market Size & Forecast

15.3 Drugs: ROA Segmentation

15.3.1 Oral Drugs: Market Size & Forecast

15.3.2 Penile Injections and Intraurethral Suppositories: Market Size & Forecast

15.3.3 Topical Formulations: Market Size & Forecast

15.4 Drugs: Distribution Channel Segmentation

15.4.1 Market Snapshot & Growth Engine

15.4.2 Retail Pharmacies: Market Size & Forecast

15.4.3 Hospital Pharmacies: Market Size & Forecast

15.4.4 Online Portals: Market Size & Forecast

15.5 Drugs: Geography Segmentation

15.5.1 Market Snapshot & Growth Engine

16 Devices

16.1 Market Overview

16.1.1 COVID-19 Impact on Erectile Dysfunction Devices Market

16.2 Market Size & Forecast

16.3 Devices: Device Type Segmentation

16.3.1 Market Snapshot & Growth Engine

16.3.2 Penile Implants: Market Size & Forecast

16.3.3 Vacuum Constriction Devices: Market Size & Forecast

16.3.4 Shock Wave Therapy Devices: Market Size & Forecast

16.3.5 Others: Market Size & Forecast

16.4 Devices: Geography Segmentation

16.4.1 Market Snapshot & Growth Engine

17 Geography

17.1 Market Snapshot & Growth Engine

17.2 Geographic Overview

18 North America

18.1 Market Overview

18.2 Market Size & Forecast

18.3 Key Countries

18.3.1 US: Market Size & Forecast

18.3.2 Canada: Market Size & Forecast

19 Europe

19.1 Market Overview

19.2 Market Size & Forecast

19.3 Key Countries

19.3.1 UK: Market Size & Forecast

19.3.2 Germany: Market Size & Forecast

19.3.3 France: Market Size & Forecast

19.3.4 Italy: Market Size & Forecast

19.3.5 Spain: Market Size & Forecast

20 APAC

20.1 Market Overview

20.2 Market Size & Forecast

20.3 Key Countries

20.3.1 Japan: Market Size & Forecast

20.3.2 China: Market Size & Forecast

20.3.3 India: Market Size & Forecast

20.3.4 Australia: Market Size & Forecast

20.3.5 South Korea: Market Size & Forecast

21 Latin America

21.1 Market Overview

21.2 Market Size & Forecast

21.3 Key Countries

21.3.1 Brazil: Market Size & Forecast

21.3.2 Mexico: Market Size & Forecast

21.3.3 Argentina: Market Size & Forecast

22 Middle East & Africa

22.1 Market Overview

22.2 Market Size & Forecast

22.3 Key Countries

22.3.1 Saudi Arabia: Market Size & Forecast

22.3.2 UAE: Market Size & Forecast

22.3.3 South Africa: Market Size & Forecast

23 Competitive Landscape

23.1 Competitive Overview

23.1.1 Overview of ED Drugs

23.1.2 Overview of ED Devices

23.2 Market Share Analysis

23.2.1 Bayer

23.2.2 Boston Scientific

23.2.3 Coloplast

23.2.4 Dong-A-Socio Holdings

23.2.5 Eli Lilly and Company

23.2.6 Pfizer

23.2.7 Teva Pharmaceuticals

23.2.8 Viatris

23.2.9 Vivus

24 Key Company Profiles

24.1 Eli Lilly and Company

24.1.1 Business Overview

24.1.2 Product Offerings

24.1.3 Key Strategies

24.1.4 Key Strengths

24.1.5 Key Opportunities

24.2 Vivus

24.2.1 Business Overview

24.2.2 Product Offerings

24.2.3 Key Strategies

24.2.4 Key Strengths

24.2.5 Key Opportunities

24.3 Pfizer

24.3.1 Business Overview

24.3.2 Product Offerings

24.3.3 Key Strategies

24.3.4 Key Strengths

24.3.5 Key Opportunities

24.4 Bayer

24.4.1 Business Overview

24.4.2 Product Offerings

24.4.3 Key Strategies

24.4.4 Key Strengths

24.4.5 Key Opportunities

24.5 Boston Scientific

24.5.1 Business Overview

24.5.2 Product Offerings

24.5.3 Key Strategies

24.5.4 Key Strengths

24.5.5 Key Opportunity

24.6 Coloplast

24.6.1 Business Overview

24.6.2 Product Offerings

24.6.3 Key Strategies

24.6.4 Key Strengths

24.6.5 Key Opportunities

24.7 Teva Pharmaceuticals

24.7.1 Business Overview

24.7.2 Product Offerings

24.7.3 Key Strategies

24.7.4 Key Strengths

24.7.5 Key Opportunities

24.8 Viatris

24.8.1 Business Overview

24.8.2 Product Offerings

24.8.3 Key Strategies

24.8.4 Key Strengths

24.8.5 Key Opportunity

24.9 Dong–A Socio Holdings

24.9.1 Business Overview

24.9.2 Product Offerings

24.9.3 Key Strategies

24.9.4 Key Strength

24.9.5 Key Opportunity

25 Other Prominent Vendors

25.1 Aurobindo Pharma

25.1.1 Business Overview

25.1.2 Product Offerings

25.1.3 Key Strategies

25.1.4 Key Strengths

25.1.5 Key Opportunities

25.2 Dr. Reddy’s Laboratories

25.2.1 Business Overview

25.2.2 Product Offerings

25.2.3 Key Strategies

25.2.4 Key Strengths

25.2.5 Key Opportunities

25.3 Cristalia

25.3.1 Business Overview

25.3.2 Product Offerings

25.3.3 Key Strategies

25.3.4 Key Strengths

25.3.5 Key Opportunity

25.4 Metuchen Pharmaceuticals

25.4.1 Business Overview

25.4.2 Product Offerings

25.4.3 Key Strategies

25.4.4 Key Strength

25.4.5 Key Opportunity

25.5 Menarini Group

25.5.1 Business Overview

25.5.2 Product Offerings

25.5.3 Key Strategies

25.5.4 Key Strengths

25.5.5 Key Opportunity

25.6 SK chemicals

25.6.1 Business Overview

25.6.2 Product Offerings

25.6.3 Key Strategies

25.6.4 Key Strengths

25.6.5 Key Opportunities

25.7 Seelos Therapeutics

25.7.1 Business Overview

25.7.2 Product Offerings

25.7.3 Key Strategies

25.7.4 Key Strengths

25.7.5 Key Opportunities

25.8 GlaxoSmithKline

25.8.1 Business Overview

25.8.2 Product Offerings

25.8.3 Key Strategies

25.8.4 Key Strengths

25.8.5 Key Opportunity

25.9 Sanofi

25.9.1 Business Overview

25.9.2 Product Offerings

25.9.3 Key Strategy

25.9.4 Key Strengths

25.9.5 Key Opportunities

25.10 Lupin

25.10.1 Business Overview

25.10.2 Product Offerings

25.10.3 Key Strategies

25.10.4 Key Strengths

25.10.5 Key Opportunity

25.11 Cipla

25.11.1 Business Overview

25.11.2 Product Offerings

25.11.3 Key Strategies

25.11.4 Key Strengths

25.11.5 Key Opportunities

25.12 Sandoz

25.12.1 Business Overview

25.12.2 Product Offering

25.12.3 Key Strategies

25.12.4 Key Strengths

25.12.5 Key Opportunity

25.13 Endo International

25.13.1 Business Overview

25.13.2 Product Offerings

25.13.3 Key Strategies

25.13.4 Key Strengths

25.13.5 Key Opportunities

25.14 Ferring Pharmaceuticals

25.14.1 Business Overview

25.14.2 Product Offerings

25.14.3 Key Strategies

25.14.4 Key Strengths

25.14.5 Key Opportunity

25.15 ADVANZ PHARMA

25.15.1 Business Overview

25.15.2 Product Offerings

25.15.3 Key Strategy

25.15.4 Key Strengths

25.15.5 Key Opportunities

25.16 Alembic Pharmaceuticals

25.16.1 Business Overview

25.16.2 Product Offerings

25.16.3 Key Strategies

25.16.4 Key Strength

25.16.5 Key Opportunities

25.17 Guangzhou Pharmaceutical Holdings

25.17.1 Business Overview

25.17.2 Product Offerings

25.17.3 Key Strategy

25.17.4 Key Strengths

25.17.5 Key Opportunity

25.18 iX Biopharma

25.18.1 Business Overview

25.18.2 Product Offerings

25.18.3 Key Strategy

25.18.4 Key Strengths

25.18.5 Key Opportunities

25.19 Dornier MedTech

25.19.1 Business Overview

25.19.2 Product Offerings

25.19.3 Key Strategies

25.19.4 Key Strengths

25.19.5 Key Opportunity

25.20 Zephyr Surgical Implants

25.20.1 Business Overview

25.20.2 Product Offerings

25.20.3 Key Strategies

25.20.4 Key Strengths

25.20.5 Key Opportunity

25.21 Augusta Medical Systems

25.21.1 Business Overview

25.21.2 Product Offerings

25.21.3 Key Strategy

25.21.4 Key Strength

25.21.5 Key Opportunity

25.22 Launch Medical

25.22.1 Business Overview

25.22.2 Product Offerings

25.22.3 Key Strategy

25.22.4 Key Strength

25.22.5 Key Opportunity

25.23 Bonro Medical

25.23.1 Business Overview

25.23.2 Product Offerings

25.23.3 Key Strategy

25.23.4 Key Strength

25.23.5 Key Opportunity

25.24 Owen Mumford

25.24.1 Business Overview

25.24.2 Product Offerings

25.24.3 Key Strategies

25.24.4 Key Strengths

25.24.5 Key Opportunity

25.25 Direx Group

25.25.1 Business Overview

25.25.2 Product Offerings

25.25.3 Key Strategy

25.25.4 Key Strength

25.25.5 Key Opportunity

25.26 Zimmer Medizin Systeme

25.26.1 Business Overview

25.26.2 Product Offerings

25.26.3 Key Strategies

25.26.4 Key Strengths

25.26.5 Key Opportunity

25.27 MTS Medical UG

25.27.1 Business Overview

25.27.2 Product Offerings

25.27.3 Key Strategy

25.27.4 Key Strengths

25.27.5 Key Opportunity

25.28 Medispec

25.28.1 Business Overview

25.28.2 Product Offerings

25.28.3 Key Strategies

25.28.4 Key Strengths

25.28.5 Key Opportunity

25.29 Inceler Medical

25.29.1 Business Overview

25.29.2 Product Offerings

25.29.3 Key Strategies

25.29.4 Key Strength

25.29.5 Key Opportunity

25.30 NOVAmedtek

25.30.1 Business Overview

25.30.2 Product Offerings

25.30.3 Key Strategy

25.30.4 Key Strength

25.30.5 Key Opportunity

25.31 WIKKON

25.31.1 Business Overview

25.31.2 Product Offering

25.31.3 Key Strategy

25.31.4 Key Strengths

25.31.5 Key Opportunity

25.32 Top Quality Group

25.32.1 Business Overview

25.32.2 Product Offerings

25.32.3 Key Strategy

25.32.4 Key Strengths

25.32.5 Key Opportunity

25.33 Promedon

25.33.1 Business Overview

25.33.2 Product Offerings

25.33.3 Key Strategy

25.33.4 Key Strengths

25.33.5 Key Opportunities

25.34 Timm medical technologies

25.34.1 Business Overview

25.34.2 Product Offerings

25.34.3 Key Strategy

25.34.4 Key Strength

25.34.5 Key Opportunity

25.35 Global Life Technologies

25.35.1 Business Overview

25.35.2 Product Offerings

25.35.3 Key Strategy

25.35.4 Key Strength

25.35.5 Key Opportunity

25.36 Urology Health Store

25.36.1 Business Overview

25.36.2 Product Offering

25.36.3 Key Strategy

25.36.4 Key Strength

25.36.5 Key Opportunity

25.37 Hims

25.37.1 Business Overview

25.37.2 Product Offerings

25.37.3 Key Strategy

25.37.4 Key Strength

25.37.5 Key Opportunity

26 Report Summary

26.1 Key Takeaways

26.2 Strategic Recommendations

27 Quantitative Summary

27.1 Product

27.2 Geography

27.2.1 North America: Product Segmentation

27.2.2 Europe: Product Segmentation

27.2.3 APAC: Product Segmentation

27.2.4 Latin America: Product Segmentation

27.2.5 Middle East & Africa: Product Segmentation

27.3 ED Drugs

27.3.1 ED Drugs: ROA Segmentation

27.3.2 ED Drugs: Distribution Channel Segmentation

27.3.3 ED Drugs: Geography Segmentation

27.4 ED Devices

27.4.1 ED Devices: Product Segmentation

27.4.2 ED Devices: Geography Segmentation

28 Appendix

28.1 Abbreviations

List Of Exhibits 

Exhibit 1             Segmentation of Global Erectile Dysfunction Treatment Market

Exhibit 2             Market Size Calculation Approach 2020

Exhibit 3             Schematic Representation of Penile Erection

Exhibit 4             Pathophysiology of Erectile Dysfunction

Exhibit 5             Signs and Symptoms of Erectile Dysfunction

Exhibit 6             ED Classification according to International Society of Impotence Research

Exhibit 7             Etiology of Erectile Dysfunction

Exhibit 8             Global Increasing Prevalence of ED 1995& 2025 (in million)

Exhibit 9             Clinical Evaluation in Patients Suffering from ED

Exhibit 10           Treatment Algorithm for ED

Exhibit 11           Impact of Emergence of Innovative ED Treatment Technologies

Exhibit 12           Impact of Increasing Strategic Agreements & Collaborations

Exhibit 13           Impact of Increasing in e-Commerce Delivery of ED Drugs & Devices

Exhibit 14           Global E-Pharmacy Revenue 2019 & 2027 (in billion)

Exhibit 15           Factors Driving the Utilization of E-pharmacy Platform among the Patient Population

Exhibit 16           Impact of Advancements in ED Drug Formulations

Exhibit 17           Impact of Increasing Incidence of Erectile Dysfunction and Other Chronic Diseases

Exhibit 18           Prevalence Rate of ED in Different Geographic Regions (%)

Exhibit 19           Increasing Global Erectile Dysfunction Prevalence (1995 & 2025) (million)

Exhibit 20           Prevalence of Erectile Dysfunction with Age (%)

Exhibit 21           Prevalence of Benign Prostatic Hyperplasia (BPH) in Different Geographies (%)

Exhibit 22           Increasing Prevalence of Diabetes Mellitus (2019−2045) (million)

Exhibit 23           Impact of Advancements in Erectile Dysfunction Treatment Devices

Exhibit 24           Various Non-Pharmacological Options for ED Treatment

Exhibit 25           Impact of Topical Formulations as a New Treatment for Impotence

Exhibit 26           Impact of Low Patient Compliance toward ED Treatment

Exhibit 27           Prevalence of ED in US and Spain (70−75 Years Old Men)

Exhibit 28           Percentage of Health-seeking Rate for ED (20−75 Years Old) in US & Germany

Exhibit 29           Factors Affecting Medical Help-seeking Behavior in ED Patients

Exhibit 30           Willingness to Discuss ED According to its Severity (%)

Exhibit 31           Impact of Key Patent Expiries & Availability of Low-cost Generics

Exhibit 32           Pfizer’s Viagra Revenue 2015-2019 ($ million)

Exhibit 33           Eli Lilly and Company’s Cialis (Tadalafil) Revenue in US ($ million)

Exhibit 34           Impact of Complications Associated with Erectile Drugs & Devices

Exhibit 35           Complications Associated with Alprostadil Injection

Exhibit 36           Side effects and Serious Adverse Events Associated with PDE-5 Inhibitors

Exhibit 37           Adverse Reactions Associated with Erectile Devices

Exhibit 38           Impact of Availability of Alternative Treatments for ED

Exhibit 39           Alternative Treatment Options for Erectile Dysfunction

Exhibit 40           Impact of Threat from Counterfeit Drugs in Treating Erectile Dysfunction

Exhibit 41           Factors Contributing to Large Counterfeit Version Market in Erectile Dysfunction

Exhibit 42           Factors Responsible for the Purchase of  Counterfeit Version of Medicines in Erectile Dysfunction

Exhibit 43           Global Erectile Dysfunction Treatment Market 2020–2026 ($ million)

Exhibit 44           Global Erectile Dysfunction Treatment Market by Geography

Exhibit 45           Global Erectile Dysfunction Treatment Market by Product

Exhibit 46           Global Erectile Dysfunction Drugs Market by ROA

Exhibit 47           Erectile Dysfunction Devices Market by Product

Exhibit 48           Five Forces Analysis 2020

Exhibit 49           Incremental Growth by Product 2020 & 2026

Exhibit 50           Global Erectile Dysfunction Treatment Market by Product

Exhibit 51           Global Erectile Dysfunction Treatment Market by Product: Incremental Growth

Exhibit 52           Global Erectile Dysfunction Treatment Market by Product: Absolute Growth

Exhibit 53           Global ED Drugs Market 2020–2026 ($ million)

Exhibit 54           Incremental Growth by ROA 2020 & 2026

Exhibit 55           Global Erectile Dysfunction Treatment Market by ROA

Exhibit 56           Common PDE-5 Inhibitors Used in the Treatment of Erectile Dysfunction

Exhibit 57           Global Erectile Dysfunction Drugs Market by Oral Drugs 2020–2026 ($ million)

Exhibit 58           Global ED Drugs Market by Penile Injections and Intraurethral Suppositories 2020−2026 ($ million)

Exhibit 59           Companies Offering Penile Injections and Intraurethral Suppositories for Treating ED

Exhibit 60           Advantages with Topical Formulations over PDE-5 Inhibitors for the Treatment of ED

Exhibit 61           Global ED Drugs Market by Topical Formulations

Exhibit 62           Incremental Growth by Distribution Channel 2020 & 2026

Exhibit 63           Global Erectile Dysfunction Drugs Market by Distribution

Exhibit 64           Global ED Drugs Market by Retail Pharmacies 2020–2026 ($ million)

Exhibit 65           Global ED Drugs Market by Hospital Pharmacies 2020–2026 ($ million)

Exhibit 66           Global ED Drugs Market by Online Pharmacies 2020−2026 ($ million)

Exhibit 67           Incremental Growth by Geography 2020 & 2026

Exhibit 68           Global ED Devices Market 2020–2026 ($ million)

Exhibit 69           Incremental Growth by Device Type 2020 & 2026

Exhibit 70           Global Erectile Dysfunction Treatment Market by Device Type

Exhibit 71           Advantages with Penile Implantation in the Treatment of Impotence

Exhibit 72           Global ED Devices Market by Penile Implants 2020−2026 ($ million)

Exhibit 73           Advantages with Vacuum Construction Devices in Treatment of Erectile Dysfunction

Exhibit 74           Global ED Devices Market by Vacuum Constriction Devices 2020−2026 ($ million)

Exhibit 75           Benefits with Low-intensity Shock Wave Therapy for ED

Exhibit 76           Global ED Devices Market by Shock Wave Therapy 2020−2026 ($ million)

Exhibit 77           Global ED Devices Market by Others Segment 2020−2026 ($ million)

Exhibit 78           Incremental Growth by Geography 2020 & 2026

Exhibit 79           Incremental Growth by Geography 2020 & 2026

Exhibit 80           Global Erectile Dysfunction Treatment Market by Geography

Exhibit 81           Global Erectile Dysfunction Treatment Market by Geography 2020: Key Countries ($ million)

Exhibit 82           Global Erectile Dysfunction Treatment Market by Geography: Incremental Growth

Exhibit 83           Global Erectile Dysfunction Treatment Market by Geography: Absolute Growth

Exhibit 84           Erectile Dysfunction Treatment Market in North America 2020–2026 ($ million)

Exhibit 85           Incremental Growth in North America 2020 & 2026

Exhibit 86           Prevalence of ED Treatment in Accordance with Age in US

Exhibit 87           Prevalence of Co-morbidities with and without ED in US

Exhibit 88           Erectile Dysfunction Treatment Market in US 2020–2026 ($ million)

Exhibit 89           Impact of Patent Expiration on Viagra and Cialis Revenue Rates 2017−2019 (in million)

Exhibit 90           Penile Implantation According to Region

Exhibit 91           Percent Probability of ED with Co-morbid Conditions in Men aged 40-49

Exhibit 92           Erectile Dysfunction Treatment Market in Canada 2020–2026 ($ million)

Exhibit 93           Erectile Dysfunction Treatment Market in Europe 2020–2026 ($ million)

Exhibit 94           Incremental Growth in Europe 2020 & 2026

Exhibit 95           Erectile Dysfunction Treatment Market in UK 2020–2026 ($ million)

Exhibit 96           Percentage of Prevalence of Erectile Dysfunction in Germany with Age (30–80 years)

Exhibit 97           Source of Potency of ED Drugs in Germany

Exhibit 98           Erectile Dysfunction Treatment Market in Germany 2020–2026 ($ million)

Exhibit 99           Erectile Dysfunction Treatment Market in France 2020–2026 ($ million)

Exhibit 100        Erectile Dysfunction Treatment Market in Italy 2020–2026 ($ million)

Exhibit 101        Prevalence Percentage of Erectile Dysfunction with Respect to Age in Spain

Exhibit 102        Erectile Dysfunction Treatment Market in Spain 2020–2026 ($ million)

Exhibit 103        Erectile Dysfunction Treatment Market in APAC 2020−2026 ($ million)

Exhibit 104        Incremental Growth in APAC 2020 & 2026

Exhibit 105        Erectile Dysfunction Treatment Market in Japan 2020–2026 ($ million)

Exhibit 106        Erectile Dysfunction Treatment Market in China 2020–2026 ($ million)

Exhibit 107        Erectile Dysfunction Treatment Market in India 2020–2026 ($ million)

Exhibit 108        Erectile Dysfunction Treatment Market in Australia 2020−2026 ($ million)

Exhibit 109        Erectile Dysfunction Treatment Market in South Korea 2020−2026 ($ million)

Exhibit 110        Erectile Dysfunction Treatment Market in Latin America 2020–2026 ($ million)

Exhibit 111        Incremental Growth in Latin America 2020 & 2026

Exhibit 112        Erectile Dysfunction Treatment Market in Brazil 2020–2026 ($ million)

Exhibit 113        Erectile Dysfunction Treatment Market in Mexico 2020−2026 ($ million)

Exhibit 114        Erectile Dysfunction Treatment Market in Argentina 2020–2026 ($ million)

Exhibit 115        Erectile Dysfunction Treatment Market in MEA 2020–2026 ($ million)

Exhibit 116        Incremental Growth in Middle East & Africa 2020 & 2026

Exhibit 117        Erectile Dysfunction Treatment Market in Saudi Arabia 2020–2026 ($ million)

Exhibit 118        Erectile Dysfunction Treatment Market in UAE 2020–2026 ($ million)

Exhibit 119        Erectile Dysfunction Treatment Market in South Africa 2020–2026 ($ million)

Exhibit 120        Key Vendors offering ED Devices

Exhibit 121        Eli Lilly and Company: Revenue Generated by Human Pharmaceutical Segment 2018 & 2019 ($ million)

Exhibit 122        Eli Lilly and Company Revenue Share by Region 2018 & 2019 ($ million)

Exhibit 123        Eli Lilly and Company R&D Investments 2017−2019 ($ million)

Exhibit 124        Eli Lilly and Company: Revenue for Cialis (tadalafil) in US 2017−2019 ($ million)

Exhibit 125        Vivus: Revenue Data 2017−2019 ($ million)

Exhibit 126        Vivus: R&D Investments from 2017−2019 ($ million)

Exhibit 127        Vivus: Revenue by Geographic Region 2019 (%)

Exhibit 128        Vivus: Revenue by Stendra/Spedra 2017−2019 ($ million)

Exhibit 129        Pfizer: R&D Investments 2017−2019 ($ million)

Exhibit 130        Pfizer: Revenue by Segment 2018 & 2019 ($ million)

Exhibit 131        Pfizer: Revenue by Geographical Regions 2019 (%)

Exhibit 132        Pfizer: Revenue by Viagra (Sildenafil citrate) 2017−2019 ($ million)

Exhibit 133        Bayer: Revenue 2017−2019 ($ million)

Exhibit 134        Bayer: R&D Investments 2017−2019 ($ million)

Exhibit 135        Bayer: Revenue by Segment 2018 & 2019 ($ million)

Exhibit 136        Bayer: Revenue by Geographic Regions 2019 (%)

Exhibit 137        Boston Scientific: Revenue in 2017−2019 ($ million)

Exhibit 138        Boston Scientific: R&D Expenses 2017−2019 ($ million)

Exhibit 139        Boston Scientific: Revenue by Segment 2018 & 2019 ($ million)

Exhibit 140        Boston Scientific: Revenue by Region in 2019 (%)

Exhibit 141        Coloplast: Revenue 2017−2019 ($ million)

Exhibit 142        Coloplast: R&D Investments 2017−2019 ($ million)

Exhibit 143        Coloplast: Revenue by Segments 2018 & 2019 ($ million)

Exhibit 144        Coloplast: Revenue by Region 2019 (%)

Exhibit 145        Teva Pharmaceuticals: Revenue 2017−2019 ($ million)

Exhibit 146        Teva Pharmaceuticals: R&D Investments 2017−2019 ($ million)

Exhibit 147        Teva Pharmaceuticals: Revenue by Regions in 2018 & 2019 (in million)

Exhibit 148        Viatris: Total Revenue 2017−2019 ($ million)

Exhibit 149        Viatris: Revenue by Region 2019 (%)

Exhibit 150        Dong- A-Socio Holdings: Revenue 2017−2019 ($ million)

Exhibit 151        Dong-A-Socio Holding: R&D Investments 2017−2019 ($ million)

             

List Of Tables   

Table 1               Key Caveats

Table 2               Currency Conversion 2013−2020

Table 3               Popular Definitions of Erectile Dysfunction

Table 4               Etiology of ED According to its Sub-type

Table 5               Investigational Drugs/Devices for the Treatment of Erectile Dysfunction

Table 6               Withdrawn/ Terminated Drug Candidates or Devices

Table 7               Comparison of Pharmacological Drugs for Treating ED

Table 8               Different Companies and their Products with Advanced & Innovative Technologies

Table 9               Key Strategic Agreements & Collaborations in Erectile Dysfunction Treatment Market

Table 10             Companies and their Products Offering Novel Erectile Dysfunction Drug Formulations

Table 11             Adverse Events & Limitations of Phosphodiesterase-5 (PDE-5) Inhibitors

Table 12             Efficacy and Safety Profile of Topical Alprostadil Cream for the Treatment of ED

Table 13             Different Companies and their Product Expiry Date

Table 14             Comparing the Activity of Popular PDE-5 Inhibitors

Table 15             Significant Vendors Offering PDE-5 Inhibitors for ED Treatment

Table 16             Significant Players Offering Penile Implants

Table 17             Significant Vendors Offering Vacuum Constriction Devices

Table 18             List of Companies Offering Low-intensity Shock Wave Therapy Products for ED

Table 19             Erectile Dysfunction Treatment Market in US by Product 2020−2026 ($ million)

Table 20             Erectile Dysfunction Treatment Market in Canada by Product 2020−2026 ($ million)

Table 21             Ratio Rates of Minimal, Moderate, and Complete ED with Medical Condition

Table 22             Erectile Dysfunction Treatment Market in UK by Product 2020−2026 ($ million)

Table 23             Erectile Dysfunction Treatment Market in Germany by Product 2020−2026 ($ million)

Table 24             Erectile Dysfunction Treatment Market in France by Product 2020−2026 ($ million)

Table 25             Erectile Dysfunction Treatment Market in Italy by Product 2020−2026 ($ million)

Table 26             Erectile Dysfunction Treatment Market in Spain by Product 2020−2026 ($ million)

Table 27             Erectile Dysfunction Treatment Market in Japan by Product 2020−2026 ($ million)

Table 28             Erectile Dysfunction Treatment Market in China by Product 2020−2026 ($ million)

Table 29             Erectile Dysfunction Treatment Market in India by Product 2020−2026 ($ million)

Table 30             Erectile Dysfunction Treatment Market in Australia by Product 2020−2026 ($ million)

Table 31             Erectile Dysfunction Treatment Market in South Korea by Product 2020−2026 ($ million)

Table 32             Erectile Dysfunction Treatment Market in Brazil by Product 2020−2026 ($ million)

Table 33             Erectile Dysfunction Treatment Market in Mexico by Product 2020−2026 ($ million)

Table 34             Erectile Dysfunction Treatment Market in Argentina by Product 2020−2026 ($ million)

Table 35             Erectile Dysfunction Treatment Market in Saudi Arabia by Product 2020−2026 ($ million)

Table 36             Erectile Dysfunction Treatment Market in UAE by Product 2020−2026 ($ million)

Table 37             Erectile Dysfunction Treatment Market in South Africa by Product 2020−2026 ($ million)

Table 38             Key Vendors in ED Drugs Market

Table 39             Other Prominent Vendors Offering ED Drugs

Table 40             Vendors Offering Various ED Devices

Table 41             Eli Lily and Company: Major Product Offerings

Table 42             Vivus: Major Product Offerings

Table 43             Pfizer: Major Product Offerings

Table 44             Bayer: Major Product Offerings

Table 45             Boston Scientific: Major Product Offerings

Table 46             Coloplast: Major Product Offerings

Table 47             Teva Pharmaceuticals: Major Product Offerings

Table 48             Viatris: Major Product Offerings

Table 49             Dong-A Socio Holdings: Major Product Offerings

Table 50             Aurobindo Pharma: Major Product Offerings

Table 51             Dr. Reddy’s Laboratories: Major Product Offerings

Table 52             Cristalia: Major Product Offerings

Table 53             Metuchen Pharmaceuticals: Major Product Offerings

Table 54             Menarini Group: Major Product Offerings

Table 55             SK Chemicals: Major Product Offerings

Table 56             Seelos Therapeutics: Major Product Offerings

Table 57             GlaxoSmithKline: Major Product Offerings

Table 58             Sanofi: Major Product Offerings

Table 59             Lupin: Major Product Offerings

Table 60             Cipla: Major Product Offerings

Table 61             Sandoz: Major Product Offerings

Table 62             Endo International: Major Product Offerings

Table 63             Ferring Pharmaceuticals: Major Product Offerings

Table 64             ADVANZ PHARMA: Major Product Offerings

Table 65             Alembic Pharmaceuticals: Major Product Offerings

Table 66             Guangzhou Pharmaceutical Holdings: Major Product Offerings

Table 67             iX Biopharma: Major Product Offerings

Table 68             Dornier MedTech: Major Product Offerings

Table 69             Zephyr Surgical Implants: Major Product Offerings

Table 70             Augusta Medical Systems: Major Product Offerings

Table 71             Launch Medical: Major Product Offerings

Table 72             Bonro Medical: Major Product Offerings

Table 73             Owen Mumford: Major Product Offerings

Table 74             Direx Group: Major Product Offerings

Table 75             Zimmer Medizin Systeme: Major Product Offerings

Table 76             MTS Medical UG: Major Product Offerings

Table 77             Medispec: Major Product Offerings

Table 78             Inceler Medical: Major Product Offerings

Table 79             NOVAmedtek: Major Product Offerings

Table 80             WIKKON: Major Product Offerings

Table 81             Top Quality Group: Major Product Offerings

Table 82             Promedon: Major Product Offerings

Table 83             Timm medical technologies: Major Product Offerings

Table 84             Global Life Technologies: Major Product Offerings

Table 85             Urology Health Store: Major Product Offerings

Table 86             Hims: Major Product Offerings

Table 87             Global Erectile Dysfunction Market by Product 2020−2026 ($ million)

Table 88             Global Erectile Dysfunction Market by Product 2020−2026 (%)

Table 89             Global Erectile Dysfunction Treatment Market by Geography 2020−2026 ($ million)

Table 90             Global Erectile Dysfunction Treatment Market by Geography 2020−2026 (%)

Table 91             North America Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)

Table 92             North America Erectile Dysfunction Treatment Market by Product 2020−2026 (%)

Table 93             Europe Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)

Table 94             Europe Erectile Dysfunction Treatment Market by Product 2020−2026 (%)

Table 95             APAC Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)

Table 96             APAC Erectile Dysfunction Treatment Market by Product 2020−2026 (%)

Table 97             Latin America Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)

Table 98             Latin America Erectile Dysfunction Treatment Market by Product 2020−2026 (%)

Table 99             Middle East & Africa Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)

Table 100           Middle East & Africa Erectile Dysfunction Treatment Market by 2020−2026 (%)

Table 101           Global Erectile Dysfunction Drugs Market by ROA 2020−2026 ($ million)

Table 102           Global Erectile Dysfunction Drugs Market by ROA 2020−2026 (%)

Table 103           Global Erectile Dysfunction Drugs Market by Distribution Channel 2020−2026 ($ million)

Table 104           Global Erectile Dysfunction Drugs Market by Distribution Channel 2020−2026 (%)

Table 105           Global Erectile Dysfunction Drugs Market by Geography 2020−2026 ($ million)

Table 106           Global Erectile Dysfunction Drugs Market by Geography 2020−2026 (%)

Table 107           Global Erectile Dysfunction Devices Market by Product 2020−2026 ($ million)

Table 108           Global Erectile Dysfunction Devices Market by Product 2020−2026 (%)

Table 109           Global Erectile Dysfunction Devices Market by Geography 2020−2026 ($ million)

Table 110           Global Erectile Dysfunction Devices Market by Geography 2020−2026 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date